Zoetis Inc. Receives Positive Opinion from European Medicines Agency for Portela® to Alleviate Osteoarthritis Pain in Cats

Reuters

09/13

<a href="https://laohu8.com/S/ZTS">Zoetis Inc.</a> Receives Positive Opinion from European Medicines Agency for Portela® to Alleviate Osteoarthritis Pain in Cats

Zoetis Inc. has announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency $(EMA)$ has issued a positive opinion recommending the granting of marketing authorization for Portela® (relfovetmab). This new monoclonal antibody therapy is designed to alleviate pain associated with osteoarthritis in cats. If approved, Portela will be the first long-acting anti-NGF monoclonal antibody therapy for cats, offering a solution that requires injections only once every three months. The European Commission is expected to make a decision during the fourth quarter of 2025, with commercial availability anticipated in the European Union in 2026. This development marks another milestone in Zoetis' commitment to advancing feline medicine and enhancing the quality of life for cats with osteoarthritis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zoetis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250912419265) on September 12, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2567903319"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2567903319\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2567903319?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-13 00:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2567903319","market":"us","top_or_hot":-1,"title":"Zoetis Inc. Receives Positive Opinion from European Medicines Agency for Portela® to Alleviate Osteoarthritis Pain in Cats","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ZTS\">Zoetis Inc.</a> Receives Positive Opinion from European Medicines Agency for Portela® to Alleviate Osteoarthritis Pain in Cats\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Zoetis Inc. has announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency <a href=\"https://laohu8.com/S/EMA\">$(EMA)$</a> has issued a positive opinion recommending the granting of marketing authorization for Portela® (relfovetmab). This new monoclonal antibody therapy is designed to alleviate pain associated with osteoarthritis in cats. If approved, Portela will be the first long-acting anti-NGF monoclonal antibody therapy for cats, offering a solution that requires injections only once every three months. The European Commission is expected to make a decision during the fourth quarter of 2025, with commercial availability anticipated in the European Union in 2026. This development marks another milestone in Zoetis' commitment to advancing feline medicine and enhancing the quality of life for cats with osteoarthritis.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zoetis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250912419265) on September 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zoetis Inc. Receives Positive Opinion from European Medicines Agency for Portela® to Alleviate Osteoarthritis Pain in Cats</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZoetis Inc. Receives Positive Opinion from European Medicines Agency for Portela® to Alleviate Osteoarthritis Pain in Cats\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-13 00:09</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ZTS\">Zoetis Inc.</a> Receives Positive Opinion from European Medicines Agency for Portela® to Alleviate Osteoarthritis Pain in Cats\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Zoetis Inc. has announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency <a href=\"https://laohu8.com/S/EMA\">$(EMA)$</a> has issued a positive opinion recommending the granting of marketing authorization for Portela® (relfovetmab). This new monoclonal antibody therapy is designed to alleviate pain associated with osteoarthritis in cats. If approved, Portela will be the first long-acting anti-NGF monoclonal antibody therapy for cats, offering a solution that requires injections only once every three months. The European Commission is expected to make a decision during the fourth quarter of 2025, with commercial availability anticipated in the European Union in 2026. This development marks another milestone in Zoetis' commitment to advancing feline medicine and enhancing the quality of life for cats with osteoarthritis.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zoetis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250912419265) on September 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0079474960.USD","symbol_name":"聯博美國增長基金A","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250912:nNDL8xshHl:1","article_id":"2567903319","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2567903319","pubTimestamp":1757693355,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Zoetis Inc. has announced that the Committee for Veterinary Medicinal Products  of the European Medicines Agency  has issued a positive opinion recommending the granting of marketing authorization for Portela . This new monoclonal antibody therapy is designed to alleviate pain associated with osteoarthritis in cats. If approved, Portela will be the first long-acting anti-NGF monoclonal antibody therapy for cats, offering a solution that requires injections only once every three months. The European Commission is expected to make a decision during the fourth quarter of 2025, with commercial availability anticipated in the European Union in 2026. This development marks another milestone in Zoetis' commitment to advancing feline medicine and enhancing the quality of life for cats with osteoarthritis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated conte","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0079474960.USD":"联博美国增长基金A","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","LU0345774391.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) ACC","LU0107464264.USD":"abrdn SICAV I - GLOBAL INNOVATION EQUITY \"A\" (USD) ACC","BK4588":"碎股","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU2360106947.USD":"BGF NUTRITION \"A4\" (USD) INC","BK4007":"制药","IE00B19Z9505.USD":"美盛-美国大盘成长股A Acc","LU0058720904.USD":"联博国际健康护理基金A","LU0385154629.USD":"贝莱德营养科学基金A2","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","LU1941712348.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"AT\" (USD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU2308191902.HKD":"BNP PARIBAS ECOSYSTEM RESTORATION \"CLASSIC\" (HKD) ACC","ZTS":"Zoetis Inc.","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU0345774631.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) INC"},"translate_title":"硕腾公司(Zoetis Inc.)获得欧洲药品管理局对Portela的积极评价®缓解猫的骨关节炎疼痛","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZTS":0.9},"content_text":"Zoetis Inc. Receives Positive Opinion from European Medicines Agency for Portela® to Alleviate Osteoarthritis Pain in Cats\n    \n\n        Zoetis Inc. has announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency $(EMA)$ has issued a positive opinion recommending the granting of marketing authorization for Portela® (relfovetmab). This new monoclonal antibody therapy is designed to alleviate pain associated with osteoarthritis in cats. If approved, Portela will be the first long-acting anti-NGF monoclonal antibody therapy for cats, offering a solution that requires injections only once every three months. The European Commission is expected to make a decision during the fourth quarter of 2025, with commercial availability anticipated in the European Union in 2026. This development marks another milestone in Zoetis' commitment to advancing feline medicine and enhancing the quality of life for cats with osteoarthritis.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zoetis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250912419265) on September 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}